A Phase 1 interventional study of DW4421 in GERD (Gastroesophageal Reflux Disease), sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
A Randomized, Open-label, Oral in healthy volunteers
1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.
This study's enrollment of 24 is below the median of 72 across 712 interventional studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 48 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cross-over
Drug: DW4421
Cross-over
Drug: DW4421
DW4421 on fasted or fed condition
Peak Plasma Concentration (Cmax)
Cmax of DW4421
Time frame: up to 48 hours
Area under the plasma concentration versus time curve (AUC)
AUC of DW4421
Time frame: up to 48 hours
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewon Pharmaceutical Co., Ltd.